

Disease course of *FLT3* mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib

Authors

Francesco Angotzi,¹ Erika Borlenghi,² Chiara Sartor,³ Maria Benedetta Giannini,⁴ Giovanni Marconi,^{4,5} Edoardo Tamellini,⁶ Mauro Turrini,⁷ Federica Loscocco,⁸ Ernesta Audisio,⁹ Vincenzo Federico,¹⁰ Calogero Vetro,¹¹ Francesco Grimaldi,¹² Andrea Visentin,¹ Felicetto Ferrara,¹³ Livio Trentin,¹ Carmela Gurrieri¹ and Federica Lessi¹

¹Hematology Unit, Department of Medicine, University of Padova, Padova; ²Department of Hematology, ASST Spedali Civili, Brescia; ³Istituto di Ematologia “Seràgnoli”, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; ⁴Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola; ⁵Hematology Unit, Department of Medical and Surgical Sciences, University of Bologna, Ospedale S. Maria delle Croci, Ravenna; ⁶Hematology Unit, Department of Engineering and Innovation Medicine, University of Verona, Verona; ⁷Hematology Unit, Division of Hematology, Valduce Hospital, Como; ⁸Hematology and Stem Cell Transplant Center, AST 1, Pesaro; ⁹Department of Oncology, Division

of Hematology, AOU City of Health and Science of Turin, Turin; ¹⁰Hematology and Stem Cell Transplant Unit, Presidio Ospedaliero “Vito Fazzi”, Lecce; ¹¹Hematology and BMT Unit, Azienda Ospedaliero Universitaria Policlinico “G. Rodolico-San Marco”, Catania; ¹²University of Naples Federico II, Naples and ¹³Division of Hematology, AORN Cardarelli, Naples, Italy

Correspondence:
F. ANGOTZI - francesco.angotzi@unipd.it

<https://doi.org/10.3324/haematol.2026.300540>

Received: January 14, 2026.
Accepted: March 24, 2026.
Early view: April 9, 2026.

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license 

Supplementary Table 1: Summary of administered therapies for eAML after first presentation and upon refractoriness/relapse. Patients relapsing only with bone marrow disease but not eAML not shown.

	First eAML presentation Total patients n = 27	Salvage treatment for eAML Total patients n = 12
ICT		
7+3+Midostaurin	5 (18.5%)	0
7+3	3 (11.1%)	0
FLAG-IDA	2 (7.4%)	2 (16.7%)
ICE	4 (14.8%)	0
Gilteritinib	5 (18.5%)	6 (50%)
Gilteritinib + TIT	5 (18.5%)	1 (8.3%)
TIT only	1 (3.7%)	0
Upfront Allo-HSCT	1 (3.7%)	0
VEN-HMAs	1 (3.7%)	1 (8.3%)
No treatment	0	2 (16.7%)

ICT: Intensive chemotherapy; FLAG-IDA: Fludarabine, cytarabine, idarubicin, G-CSF; ICE: Idarubicin, cytarabine, etoposide; TIT: Triple intrathecal therapy; Allo-HSCT: allogeneic hematopoietic stem cell transplant; VEN-HMAs: Venetoclax + hypomethylating agents (decitabine or azacitidine).

Supplementary Figure 1: Survival curve for the whole population with eAML

